Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 20, 2016 08:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces FDA Fast Track Designation for ProTmune™

SAN DIEGO, June 20, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and...